US FDA approves label update for Kite's (GILD) Yescarta for relapsed or refractory PCNSL

The FDA's approval for Kite's Yescarta label update reflects a significant advancement in the treatment options for patients with relapsed or refractory PCNSL, potentially enhancing Gilead Sciences' market position in the oncology space.

Newsquawk StaffPublished On the live feed at 15 more headlines followed before this page went public
Newsquawk headlinesUTC

Iran's Foreign Ministry spokesperson says US-Iran talks for Friday are over for now, unsure when negotiations might restart

Stellantis (STLAM IM) CFO says co. is still in negotiations with suppliers over payments related to suspended EV models

US FDA approves label update for Kite's (GILD) Yescarta for relapsed or refractory PCNSL

Canadian Unemployment Rate (Jan) 6.5% vs. Exp. 6.8% (Prev. 6.8%)

Canadian Participation Rate (Jan) 65% (Prev. 65.4%)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This regulatory approval could lead to increased sales and investor interest, particularly as the biotech sector looks for growth catalysts. Watch for potential movement in GILD's stock price as this could drive sentiment and influence healthcare valuations more broadly.

Related headlines

The whole workspace, free to try.

Try it free